Related by context. All words. (Click for frequent words.) 75 diastolic BP 74 HbA1c levels 72 mm Hg 72 HbA 1c 72 mmHg 71 mm Hg systolic 69 #mmHg [002] 69 HbA 1c levels 69 systolic blood pressure 69 HbA1C levels 68 #/#mmHg 68 mmHg systolic 68 mmHg diastolic 68 Hb A1C 67 hemoglobin A1c HbA1c 67 normotensive 67 antihypertensive medications 67 mL/min/#.# m 2 67 #mmHg [001] 67 mm Hg diastolic 66 #.#/#.# mm Hg [002] 66 lowest tertile 66 sUA 66 fasting plasma glucose 66 serum creatinine levels 66 serum potassium 66 proteinuria 65 glycosylated hemoglobin HbA1c 65 nondiabetic patients 65 MMSE score 65 baseline HbA1c 65 plasma glucose 65 hemoglobin A1c levels 65 #.#mmol L [002] 65 serum urate 65 plasma glucose levels 65 fasting glucose levels 64 creatinine clearance 64 MADRS score 64 intima media thickness 64 #.#mmHg 64 serum phosphate levels 64 urinary albumin excretion 64 albumin excretion 64 systolic 64 glycated hemoglobin HbA1c 64 mg dL 64 UACR 64 insulin detemir 64 hypertensives 64 #mg/dL [001] 64 LVEF 63 mmol l 63 serum concentrations 63 highest tertile 63 diastolic blood pressure 63 fasting insulin 63 glycated hemoglobin levels 63 #.#/#.# mmHg [001] 63 nicardipine 63 serum testosterone 63 fasting glucose 63 lispro 63 serum uric acid 63 peak VO2 63 NPH insulin 63 severe exacerbations 63 A1C levels 63 nmol L 63 Cmax 63 systolic diastolic 63 oxycodone CR 63 elevated LDL cholesterol 63 postintervention 63 fasting plasma glucose FPG 63 carotid IMT 63 glycated hemoglobin 63 systolic blood pressures 63 nonobese 63 serum cortisol 63 diastolic pressures 63 serum calcium levels 63 LV dysfunction 63 creatinine ratio 62 ATACAND 62 CI -#.# 62 fasting triglyceride levels 62 systolic dysfunction 62 -#.# mm Hg 62 β blockers 62 neutrophil counts 62 serum phosphorus 62 antihypertensive medication 62 cardiovascular mortality 62 hip BMD 62 fasting blood glucose 62 HOMA IR 62 P = .# 62 nonsignificant 62 CrCl 62 #.#mg/dL 62 postprandial glucose 62 serum urate levels 62 prolactin levels 62 MMSE scores 62 tertiles 62 serum sodium 62 nonfatal MI 62 subclinical hypothyroidism 62 triacylglycerol concentrations 62 postoperative mortality 62 noncardiovascular mortality 62 hemoglobin A1C 62 moderate renal impairment 62 PaO 2 62 urinary albumin 62 albuminuria 62 plasma triglycerides 62 lumbar spine BMD 62 serum vitamin D 62 p = .# [002] 62 CVD mortality 62 transaminase levels 62 plasma homocysteine 61 HbA1C 61 HbA1c 61 glycemia 61 % Confidence Interval 61 mg dl 61 alanine aminotransferase 61 elevated creatinine 61 #mg/day [001] 61 irbesartan 61 serum phosphate 61 incontinence episodes 61 posttreatment 61 ejection fractions 61 μmol L 61 creatinine levels 61 tertile 61 PSADT 61 pCR 61 apnea hypopnea index 61 p = NS 61 triglyceride levels 61 endometrial thickness 61 glycosylated hemoglobin 61 CDAI score 61 biochemical recurrence 61 aspartate aminotransferase AST 61 % CI #.#-#.# [003] 61 periprocedural 61 beta blocker therapy 61 A1c levels 61 serum IGF 61 REYATAZ r arm 61 T2DM 61 leukocyte count 61 Fasting plasma glucose 61 hypoglycemic events 61 triglyceride concentrations 61 ng dL 61 binary restenosis 61 postprocedure 61 nonfasting triglyceride levels 61 glomerular filtration rate 61 atherogenic dyslipidemia 61 nocturnal hypoglycaemia 61 adjunctive placebo 61 microalbuminuria 61 QTc interval 61 reflux symptoms 61 serum PSA 61 serum triglycerides 61 definite stent thrombosis 61 tHcy 61 pg mL 61 pulmonary capillary wedge 61 μg kg 61 confidence interval #.#-#.# 61 depressive symptoms 61 triglyceride concentration 60 diastolic blood pressures 60 SGRQ 60 rimonabant #mg 60 mmol L 60 supine systolic 60 confidence interval CI 60 albumin excretion rate 60 thyrotropin levels 60 PASI scores 60 normal ULN 60 serum lipid levels 60 #.#/#.# mm Hg [001] 60 hemoglobin concentrations 60 serum calcium 60 recurrent venous thromboembolism 60 hypopneas 60 Primary endpoints 60 CK MB 60 #OHD levels 60 % CI #.#-#.# [006] 60 mL kg 60 CI #.#-#.# [001] 60 pmol L 60 mmol liter 60 valsartan 60 extrapyramidal symptoms 60 μg dL 60 BENICAR HCT 60 postoperative AF 60 alanine aminotransferase ALT 60 multivariable adjusted 60 estimated glomerular filtration 60 neurodevelopmental impairment 60 salivary flow 60 arterial thromboembolic events 60 virologic failure 60 mean baseline HbA1c 60 thiazide diuretics 60 baseline A1C 60 flow mediated dilation 60 LV ejection fraction 60 MetS 60 nmol liter 60 angiotensin II receptor blockers 60 diastolic pressure 60 β blocker 60 antihypertensive therapy 60 mIU L 60 symptomatic intracerebral hemorrhage 60 severe hypoglycemia 60 intact parathyroid hormone 60 TEAEs 60 pg ml 60 BENICAR 60 -#.# mg dL [002] 60 plasma cortisol 59 glomerular filtration 59 postop 59 eGFR 59 aminotransferases 59 asthma exacerbation 59 primary aldosteronism 59 hypertensive patients 59 serum estradiol 59 clinically meaningful improvements 59 lipid levels 59 asthma exacerbations 59 sodium excretion 59 NATRECOR R 59 tirofiban 59 colorectal adenoma 59 hours postdose 59 plasma concentrations 59 corrected QT interval 59 premenopausal 59 g dl 59 confidence intervals CIs 59 elevated ALT 59 NSTE ACS 59 OGTT 59 umol L 59 plasma renin 59 RLS symptoms 59 #mm Hg 59 metabolic parameters 59 adenoma recurrence 59 Systolic 59 detemir 59 serum bilirubin 59 timepoints 59 comorbid conditions 59 adiponectin concentrations 59 abdominal circumference 59 #mg dose [003] 59 antihypertensive drugs 59 tHcy concentrations 59 elevated LDH 59 advanced adenomas 59 protein excretion 59 urinary sodium excretion 59 postprandial blood glucose 59 IRLS score 59 NIHSS score 59 QTc 59 Pred Forte 59 resistant hypertension 59 urinary symptoms 59 mg BID 59 platelet reactivity 59 LDL C 59 ABPM 59 fraction LVEF 59 antidiabetic medication 59 serum homocysteine 59 homocysteine concentrations 59 lipid lowering agents 59 euthyroid 59 carotid intima media 59 mEq L 59 recurrent VTE 59 mL/min/#.# m2 59 serum cholesterol 59 serum glucose 59 hsCRP 59 benazepril 59 ipsilateral stroke 59 #.#/#.# mm Hg [003] 59 nondepressed 59 perimenopausal women 59 nocturnal awakenings 59 macroalbuminuria 59 mg d 59 baseline serum creatinine 59 lipid lowering medications 59 Diastolic 59 μg L 59 Apgar scores 59 serum testosterone levels 59 PSA nadir 59 lipid lowering therapy 59 lymphocyte counts 59 annualized relapse 59 CK # plasma concentrations 59 nonfatal stroke 59 ALT elevation 59 urine albumin 59 inflammatory biomarkers 59 subclinical hyperthyroidism 59 preoperatively 59 preoperative PSA 59 hyperlipidaemia 59 depressive symptom 59 isolated systolic hypertension 59 Ejection Fraction 58 salivary cortisol 58 serum folate concentrations 58 HDRS 58 SHBG levels 58 candesartan 58 Plasma concentrations 58 severe hypoglycaemia 58 % CI #.#-#.# [008] 58 lopinavir r arm 58 apnea hypopnea 58 serum magnesium 58 p = #.# [003] 58 #mg/dl 58 aspartate aminotransferase 58 attain statistical significance 58 FEV1 58 achieved ACR# 58 arterial stiffness 58 HDL C 58 symptom severity 58 gout flares 58 labetalol 58 mg TID 58 HbA 1C 58 impaired fasting glucose 58 odds ratios ORs 58 APTIVUS r 58 hemodilution 58 transferrin saturation 58 solifenacin 58 nonfasting 58 dapagliflozin plus 58 symptomatic VTE 58 urate lowering therapy 58 thromboembolic 58 PANSS scores 58 OAB symptoms 58 mIU ml 58 SGPT 58 hypoglycemic episodes 58 dietary calcium intake 58 virologic response 58 IOP lowering 58 glargine 58 blood Phe levels 58 FDA defined valvulopathy 58 lipid profiles 58 urinary excretion 58 cardiovascular morbidity 58 HBeAg seroconversion 58 Secondary efficacy endpoints 58 CR nPR 58 infarct size 58 Hb A1c 58 Prehypertension 58 Triglyceride levels 58 cholesterol LDL C 58 retinal thickness 58 endoscopic remission 58 glycosylated hemoglobin levels 58 statin monotherapy 58 EDSS scores 58 sUA levels 58 eptifibatide 58 maximal doses 58 morphometric vertebral fractures 58 lymphocyte count 58 % CI #.#-#.# [004] 58 secondary efficacy endpoint 58 hemodynamic parameters 58 echocardiographic parameters 58 TT genotype 58 undetectable viral 58 oral antidiabetes 58 thromboembolic events 58 #.#ng/ml 58 salmeterol fluticasone 58 exhaled nitric oxide 58 severe renal impairment 58 multivariate adjustment 58 biphasic insulin aspart 58 estimated GFR 58 symptom exacerbation 58 clinically meaningful improvement 58 kcal d 58 thromboembolism 58 Secondary endpoints 58 reinfarction 58 achieved statistical significance 58 covariate 58 troponin T 58 allopurinol 58 serum phosphorous 58 plasma folate 58 n = 58 HCTZ 58 HER2 expression 58 systolic hypertension 58 femoral neck BMD 58 OADs 58 hypophosphatemia 58 LVSD 58 ALT elevations 58 macrovascular 57 g dL 57 depressive symptomatology 57 asymptomatic carotid stenosis 57 clinically meaningful reductions 57 Depressive symptoms 57 BMI z 57 SGOT 57 baseline FEV1 57 acute gout flares 57 gastric pH 57 diastolic hypertension 57 primary hypercholesterolemia 57 pretreatment baseline 57 dose atorvastatin 57 tapentadol ER 57 EDSS score 57 ramipril 57 carotid artery intima media 57 mcg BID 57 mg/m2 dose 57 cotinine levels 57 hypogonadal 57 polyp recurrence 57 androgen suppression 57 preserved ejection fraction 57 paricalcitol 57 plasma HCV RNA 57 Y BOCS 57 NIH CPSI 57 abdominal adiposity 57 insulin glargine 57 SCr 57 preintervention 57 diameter stenosis 57 lipid lowering drugs 57 macrovascular events 57 % CI #.#-#.# [007] 57 CC genotype 57 arterial thickening 57 Score DAS# 57 systemic corticosteroid 57 plasma homocysteine levels 57 ng ml 57 total cholesterol triglycerides 57 racemic albuterol 57 renal dysfunction 57 6MWD 57 hemoglobin A1c 57 intraocular pressure IOP 57 ≥ 57 posttransplant 57 LANTUS R 57 hypogonadal men 57 blood Phe 57 antibody titer 57 urinary oxalate 57 LDL cholesterol concentrations 57 density lipoprotein cholesterol 57 haemorrhagic stroke 57 = #.#-#.# 57 Postoperative 57 NATRECOR ® 57 pulmonary artery pressure 57 peak expiratory flow 57 intraocular pressure 57 QTcF 57 nonfatal myocardial infarction 57 corticosteroid dose 57 NNT = 57 tolvaptan 57 baseline Hb 57 systolic pressure 57 elevated serum creatinine 57 elevated triglyceride levels 57 transaminases 57 serum CRP 57 elevated fasting glucose 57 serum PTH 57 neurodevelopmental outcomes 57 #mg/day [002] 57 logistic regression model 57 hsCRP levels 57 pulmonary exacerbations 57 rizatriptan 57 adjunctive ABILIFY 57 p = #.# [002] 57 Intraocular pressure 57 + PH# 57 C reactive protein 57 myocardial infarction MI 57 -#.# ± [002] 57 urinary N telopeptide 57 atorvastatin #mg 57 dyslipidaemia 57 advanced adenoma 57 sinus rhythm 57 renal function 57 timepoint 57 urinary calcium 57 progression TTP 57 AST ALT 57 orthostatic hypotension 57 elevated CRP 57 certolizumab 57 mcg mL 57 covariates 57 IPSS 57 oral antidiabetic medication 57 PCWP 57 WOMAC pain 57 dose clopidogrel 57 NIHSS 57 hyperglycaemia 57 #.#mmol l [002] 57 DAS# [002] 57 atheroma volume 57 abciximab 57 mmol L. 57 QTc intervals 57 pulmonary exacerbation 57 DAS# remission 57 eosinophil count 57 tumor histology 57 4mg/kg 57 LUTS 57 Index CDAI 57 recurrent atrial fibrillation 57 ADCS ADL 57 microvascular complications 57 p = #.# [004] 57 mg simvastatin 57 apolipoprotein B 57 IELT 57 platelet inhibition 57 desvenlafaxine succinate 57 patients undergoing CABG 57 VT VF 57 postoperative morbidity 57 Diastolic pressure 57 severe hypoglycemic 57 elevated IOP 57 blood glucose concentrations 57 lifetime abstainers 57 EBRT 57 fasting plasma 57 inflammatory markers 57 renal artery stenosis 57 perioperatively 57 laboratory abnormalities 57 cerebral infarction 57 sd = 57 overt hypothyroidism 56 ng mL 56 lung function 56 CRESTOR #mg 56 aminotransferase levels 56 YMRS 56 methotrexate monotherapy 56 elevated depressive symptoms 56 comorbidities 56 rCBF 56 nonfasting triglycerides 56 coronary calcification 56 elevated hsCRP 56 POAG 56 elevated troponin 56 oxygen saturations 56 urinary cortisol 56 Crohn Disease Activity 56 plasma lipids 56 baseline CD4 56 candesartan cilexetil 56 spontaneous preterm delivery 56 nonvertebral fractures 56 LDL cholesterol levels 56 TC HDL 56 cerebral oxygenation 56 #mg doses [002] 56 liver histology 56 highest quintile 56 HRQL 56 unfractionated heparin 56 renal insufficiency 56 nighttime awakenings 56 prolactin elevation 56 hypertensive 56 methacholine challenge 56 coronary stenosis 56 antidiabetic medications 56 calculated creatinine clearance 56 leukocyte counts 56 Secondary endpoints include 56 oxygen desaturation 56 perioperative complications 56 tamsulosin 56 index BMI 56 Apidra ® 56 serum sodium levels 56 postdischarge 56 serum ALT 56 Subgroup analyzes 56 nondiabetics 56 URTI 56 Brief Psychiatric 56 prostate cancer CaP 56 nmol l 56 NYHA functional class 56 creatine phosphokinase 56 arterial oxygen saturation 56 serum clusterin levels 56 oral prednisone 56 receiving ISENTRESS 56 coronary artery calcification 56 A1c 56 glimepiride 56 GERD symptoms 56 Lantus ® 56 mcg QD 56 hypertension 56 sodium nitroprusside 56 SBP DBP 56 triglycerides TG 56 thyroid stimulating hormone 56 sociodemographic factors 56 Hemoglobin A1c 56 serum lipids 56 ziprasidone 56 fatal myocardial infarction 56 ml kg 56 ng dl 56 diastolic function 56 hydroxyvitamin D levels 56 magnesium intake 56 antiretroviral naive 56 HF hospitalization 56 dosing frequency 56 plasma urate 56 hepatic function 56 serum ferritin 56 statistically nonsignificant 56 #mg BID [003] 56 locomotor activity 56 multivariable analysis 56 NSTEMI 56 Montgomery Åsberg Depression 56 arterial stiffening 56 μg d 56 serum creatinine 56 Montgomery Asberg Depression 56 cardio respiratory fitness 56 lactate dehydrogenase LDH 56 ug kg 56 Calcium intake 56 hemoglobin Hb 56 secondary endpoint 56 carotid stenosis 56 % CI #.#-#.# [002] 56 folate intake 56 #.#mmol L [001] 56 fluticasone salmeterol 56 μg liter 56 fasting serum 56 left ventricular dysfunction 56 prednisone prednisolone 56 oral hypoglycemic agents 56 univariate analysis 56 glucose intolerant 56 plasma leptin 56 Lucentis monotherapy 56 nocturia 56 mean serum phosphorus 56 diuretic chlorthalidone 56 antiandrogen 56 diastolic dysfunction 56 inhaled budesonide 56 gadolinium enhancing lesions 56 x ULN 56 pulmonary arterial 56 hypokalemia 56 hypoglycaemic episodes 56 placebo fluoxetine 56 serum bicarbonate 56 contrast induced nephropathy 56 pyridostigmine 56 T1DM 56 Hb levels 56 mRS 56 PREZISTA r arm 56 glycaemia 56 baseline FEV 56 dose colchicine 56 specific antigen PSA 56 QALE 56 paroxysmal AF 56 serum phosphorus levels 56 plasma renin activity 56 mg BID dose 56 distensibility 56 serum LDL cholesterol 56 PRADAXA #mg 56 prehypertensive 56 CLA supplementation 56 nadolol 56 cardiorespiratory fitness 56 RLAI 56 iPTH 56 HIV HCV coinfected 56 GnRH agonist 56 antiplatelet drugs 56 macrovascular disease 56 undetectable HBV DNA 56 biochemical relapse 56 acute cholecystitis 56 non aspirin NSAIDs 56 symptomatic intracranial hemorrhage 56 treat NNT 56 CI #.#-#.# [002] 56 CR CRu 56 Unified Parkinson Disease 56 anticoagulation therapy 55 spontaneous preterm birth 55 ACEIs 55 subcutaneous insulin 55 lipid parameters 55 thrombotic events 55 SSRI SNRI 55 EDARBI 55 cerebrovascular events 55 Serum creatinine 55 systolic function 55 pentoxifylline 55 univariate analyzes 55 FOLPI 55 Baseline characteristics 55 tipranavir r 55 adiponectin levels 55 serum leptin 55 preeclamptic 55 nmol L. 55 HRQOL 55 Forced expiratory volume 55 paclitaxel eluting stents 55 p ≤ 55 leucopenia 55 serum BDNF 55 Ishak fibrosis score 55 aldosterone antagonist 55 isoprostane 55 olmesartan 55 -#.# mmol L 55 loop diuretics 55 flutamide 55 conjugated equine estrogen 55 acromegalic patients 55 â ‰ ¥ 55 concomitant medications 55 AUC0 55 elevated uric acid 55 rosuvastatin #mg 55 IFN beta 55 ginkgo biloba extract 55 oral diclofenac 55 exhaled NO 55 Secondary endpoints included 55 atazanavir ritonavir 55 postoperative complications 55 placebo 55 left ventricular ejection 55 coronary revascularization 55 Stent thrombosis 55 oral prednisolone 55 ACE inhibitor ramipril 55 baroreflex sensitivity 55 mild renal insufficiency 55 AUCs 55 airflow obstruction 55 #mg/dL [002] 55 nondiabetic 55 IIIa inhibitors 55 P ≤ 55 periprocedural MI 55 urate levels 55 CD4 + cell 55 multivariate analyzes 55 serum triglyceride 55 #OHD 55 folate supplementation 55 -#.# mg dL [001] 55 metabolic syndrome MetS 55 steroid dexamethasone 55 SpO 2 55 LEXIVA r 55 nonadherent 55 detrusor overactivity 55 poor metabolizers 55 rheumatoid factor 55 placebo dexamethasone 55 hydroxyvitamin D concentrations 55 thyroid hormone levels 55 serum aminotransferase levels 55 urinary protein 55 hypercholesterolaemia 55 reach statistical significance 55 #μg [001] 55 recurrent ischemia 55 postoperatively 55 NYHA class 55 hypocaloric diet 55 nocturnal hypoglycemia 55 #mg dose [001] 55 serum albumin 55 pT3 55 XIENCE V PROMUS Stent 55 autoantibody levels 55 postoperative complication 55 mmHg p = 55 IDDM 55 prehypertension 55 systolic diastolic blood 55 milliliters mL 55 chlorthalidone 55 CPAP adherence 55 perioperative mortality 55 cranial irradiation 55 discontinuations due 55 HBV DNA levels 55 mineral density 55 coadministration 55 chlorambucil 55 Fasting glucose 55 nonvertebral fracture 55 serum HBV DNA 55 oocytes retrieved 55 mmol 55 angiotensin converting enzyme 55 intensive statin therapy 55 per deciliter mg 55 QoL 55 detrusor 55 confounding variables 55 abacavir lamivudine 55 aripiprazole 55 complete cytogenetic response 55 affective psychosis 55 HAM D# scores 55 plasma uric acid 55 echocardiographic 55 bioavailable testosterone 55 psychiatric comorbidities 55 HDL cholesterol triglycerides 55 fractional shortening 55 titration regimen 55 #.#g/day 55 parous women 55 Kaplan Meier analysis 55 test OGTT 55 nonsignificant difference 55 multivariate Cox 55 coronary blockages 55 HAM D# 55 CDAI 55 conditional logistic regression 55 HRQoL 55 sweat chloride 55 SHBG 55 ischemic cardiomyopathy 55 spontaneous bowel movements 55 homocysteine levels 55 eNO 55 UPDRS 55 erythrocyte sedimentation rate 55 deep venous thromboses 55 generalized edema 55 lipid lowering medication 55 CHD mortality 55 glulisine 55 Charlson comorbidity index 55 angiographic restenosis 55 rhinoconjunctivitis 55 carotid artery thickness 55 ventricular enlargement 55 glucose concentrations 55 recurrent ischemic 55 thyroxine 55 cortisol secretion 55 metabolite concentrations 55 #ng/ml 55 bezafibrate 55 QTc prolongation 55 serum potassium levels 55 glucose tolerance test 55 composite endpoint 55 serum parathyroid hormone 55 intima media thickness IMT 55 Visual Analogue Scale VAS 55 REYATAZ ritonavir 55 ALT flares 55 urinary cadmium 55 mg orally 55 ejection fraction 55 SUVmax 55 antigen PSA levels 55 multivariable adjustment 55 MACCE 55 intravitreal injections 55 placebo p = 55 nonobstructive CAD 55 AOR = 55 spirometric 55 tolterodine ER 55 pre menopausal 55 potential confounders 55 atherosclerotic renal artery stenosis 55 left ventricular systolic 55 dizziness nausea diarrhea 55 amlodipine 54 alteplase 54 ACEI ARB 54 left ventricular hypertrophy 54 Ramipril 54 virological response 54 dose statin therapy 54 ADCS CGIC 54 recurrent UTI 54 RSV hospitalizations 54 spine BMD 54 -#.# mmHg 54 cerebrovascular accident 54 myocardial infarction stroke 54 undetectable HCV RNA 54 dose titration 54 upper gastrointestinal bleeding 54 hemoglobin concentration 54 potassium sparing diuretics 54 MADRS 54 GH deficiency 54 TDF FTC 54 LDL triglycerides 54 PANSS 54 subscale scores 54 A1C 54 serum retinol 54 comorbid illnesses 54 mg dose 54 salmeterol HFA MDI 54 myocardial infarction 54 triacylglycerol 54 lamivudine monotherapy 54 bronchodilation 54 nitroprusside 54 pramlintide 54 hippocampal volume 54 fasting triglycerides 54 eplerenone 54 nadroparin 54 PUFA intake 54 Operative mortality 54 subclinical atherosclerosis 54 dosage regimens